Crinetics Pharmaceuticals, Inc. (CRNX) · Aug 19, 2026 · Acquisition

Crinetics supplements Vertex merger proxy after lawsuits, leaves $85 offer unchanged

Merger reaffirmed — Board still recommends the $85.00-per-share merger; shareholder vote scheduled for August 28

New proxy disclosures detail valuation ranges, banker fees and litigation claims, but do not alter the $85-per-share Vertex merger or board recommendation.

The core deal is unchanged and was already known. Vertex’s $85-per-share acquisition was announced July 6, and the shareholder meeting was already scheduled for August 28. 〔0〕 The new filing is a proxy supplement responding to three shareholder lawsuits and several demand letters, not a revised offer or a new strategic event.

The added valuation detail broadly supports, but does not clearly improve, the $85 price. J.P. Morgan’s public-company comparison produced a very wide implied range of $30.75 to $95.00 per share, while its selected-transaction analysis produced $47.75 to $84.75. Its discounted-cash-flow range was $68.25 to $86.00, putting the merger consideration near the top of that range rather than materially below it. The filing also discloses management’s risk-adjusted 2030 revenue forecast of $1.057 billion and approximately $1.209 billion of net cash (J.P. Morgan opinion and Management Forecasts sections).

Valuation referenceImplied value or disclosed amount
Merger consideration$85.00 per share (J.P. Morgan opinion disclosures)
J.P. Morgan public trading multiples$30.75–$95.00 per share (J.P. Morgan opinion — Public Trading Multiples)
J.P. Morgan selected transactions$47.75–$84.75 per share (J.P. Morgan opinion — Selected Transactions Analysis)
J.P. Morgan discounted cash flow$68.25–$86.00 per share (J.P. Morgan opinion — Discounted Cash Flow Analysis)
2030 risk-adjusted revenue forecast$1,057 million (Management Forecasts)
Estimated net cashApproximately $1,209 million (J.P. Morgan opinion — Discounted Cash Flow Analysis)

The litigation adds process friction, not a changed economic outcome. The complaints seek additional disclosures, an injunction against closing unless disclosures are added, or damages, but Crinetics denies the allegations and continues to recommend approval. 〔1〕 The practical read is modestly more execution scrutiny ahead of the vote, without evidence in this filing that the transaction price or closing timetable has deteriorated.

The supplement increases visibility into banker incentives and negotiations. J.P. Morgan’s estimated fee is approximately $69.4 million, with most payable only if the merger closes, while Leerink Partners’ fee is approximately $60.8 million; those disclosures are relevant to shareholder review but do not change the recommendation or consideration. Net: this is a largely anticipated transaction confirmation with more disclosure and legal noise, so the filing reads neutral rather than as a new positive or negative repricing event.

What to watch next

Shareholder vote on the merger, August 28, 2026

Original filing on SEC EDGAR

More Crinetics Pharmaceuticals, Inc. news

Crinetics supplements Vertex merger proxy after lawsuits, leaves $85 offer unchanged | CRNX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.